A study found that injecting mesenchymal stem cells into periocular tissue effectively reduces eye inflammation without ...

Graft-versus-host disease (GVHD) is a common and severe complication that occurs after stem cell transplantation, where the ...

A phase 2 study evaluated the use of ruxolitinib plus standard GVHD prophylaxis in patients with myelofibrosis undergoing ...

Researchers from Japan have found that treatment with mesenchymal stromal cells (MSCs) increased regulatory T cells while decreasing inflammatory TH1 and TH17 cells, highlighting MSCs' potential as a ...

Niktimvo, a colony stimulating factor-1 receptor-blocking antibody, was approved in 2024 for the treatment of chronic graft-vs-host disease (GVHD) after failure of at least 2 prior lines of ...

Mesoblast ran an additional clinical trial to support its latest application, which revealed that in 54 paediatric patients with severe, acute GvHD, Ryoncil treatment achieved a complete response ...

Cite this: Technology Insight: ECP for the treatment of GvHD-Can We Offer Selective Immune Control Without Generalized Immunosuppression? - Medscape - Jun 01, 2006. SR Marshall is a ...

In the 132-patient ROCKstar study, almost three quarters of chronic GVHD patients treated with a daily oral dose of belumosudil (KD025) saw an improvement in symptoms that lasted for at least six ...

Dr. Shimmura explained that this therapy offers two major benefits: it reduces inflammation and promotes healing at the same ...

Study finds mesenchymal stem cells injected into periocular tissue effectively reduce inflammation in the eyes without ...